pharmaq-innovation.jpg

Did you know...

We reinvest around 20% of our revenue in research and development to provide environmentally sound, safe and efficacious products for the aquaculture industry.

verdikjede282.png

> Learn more about our value chain

vc_verdikjede.png

Identify

vc_identify.jpg

Samples from diseased fish of a variety of species of different geographical origin are sent directly to our dedicated team of bacteriologists and virologists in R&D for cultivation and characterization. At this stage, the key to success is the joint efforts of our PHARMAQ field force in different regions of the world and cooperation with our external partners including various scientific institutes, fish farmers and fish health personnel.

Cultivation and characterization of virus and bacteria challenge our R&D people. In some cases it even results in identification of previous uncharacterized pathogens.

PHARMAQ actively utilizes IPR actively to secure freedom to operate and to create value and competitive advantages. Several patents and patent applications covering future products and technologies are held by the company.

Research & Development

vc_process.jpg

Identifying the best solutions to our customers' needs for new vaccines and fish health products, requires dedicated and targeted R&D efforts. Effective vaccine solutions to different bacterial and viral diseases depend upon extensive research and development and a broad range of competencies and highly equipped technical facilities.

The causative pathogen for a disease is usually already known before we start development of new vaccine component. Challenges lies in the ability to identify and characterize the best protective antigens, how to produce them and to optimize the way in which the antigens are presented to the fish in order to obtain protection against disease.

The rate of success of introducing new products and development of efficient processes is founded on the firm commitment to re-invest in R&D and related competencies in the PHARMAQ value chain.

Documentation and registration

vc_documentation.jpg

Documentation requirements for new products are strictly regulated. Through all steps of research, development and product testing the interaction with the PHARMAQ regulatory department is essential in establishing high quality product documentation for different regulatory bodies around the world.

Our vaccines and therapeutics hold veterinary medicinal product licenses in each country in which they are sold. These licenses certify to the quality, safety, efficacy and environmental effects of each product in the local environment.

Production

vc_prod.jpg

All PHARMAQ's vaccines are manufactured at our well recognized facility at Overhalla in Norway. Specific diseases in different farmed fish species and regions need separate vaccine and therapeutic solutions. Careful production planning and logistics combined with flexibility, new ideas and core competencies in vaccine manufacturing make this possible.

Quality is documented in every step from preparation of seed material to final product and throughout the product life cycle. Our quality system ensures that the defined product is manufactured and tested the same way every time, securing that the final product meets the requirements regarding quality, safety and efficacy. The final products are released by a Qualified Person (QP), approved by the authorities. As a pharmaceutical company we are frequently inspected by different national regulatory authorities in order to prove our standards.

Customer Service

customer_service_2.jpg

By providing environmentally sound, safe and efficacious health products and services to our global aquaculture customers, we will continue to meet our main objective namely to be selected by our customers as their preferred supplier and partner. We put pride in being flexible and create customer satisfaction through high quality service and products.

We can only be successful in this effort if our customers produce predictable yields and healthy profits.

PHARMAQs Pharmacovigilance system is an integral part of post marketing activities in the field of veterinary medicinal products.

E!5934 New-Vac is funded by:

eurostars_logo_pos.jpg

External collaboration

To nurture innovation across our value chain we work through an extensive global network within the aquaculture business and in close cooperation with various local scientific institutes, authorities, fish farmers and fish health personnel. For us, this is an important contribution to idea creation and the best utilization of resources, yielding a unique basis for development and supply of excellent products to existing and new markets.

We are always open for new partners and proposals to join our way to make aquaculture progress.

External funded R&D projects, ongoing:

Improved vaccines against intracellular pathogens in aquaculture - combining PHARMAQ and Isconova technology
- The project is funded by Eurostars - E!5934 New-Vac.

poweredby.jpg

Development of a vaccine for the Korean flat fish aquaculture industry.
- Innovation Norway, IFU 2010 - 2013

Et flerfaglig prosjekt for å forbedre badebehandling mot lakselus (Topilouse)
- Fiskeri- og havbruksnæringens forskningsfond (FHF) 900466 (2010-2011)

Identifikasjon av ukjente sykdomsagens.
- Norwegian Research council, 200511 (2010-2011).

Indo-Norwegian platform on fish and shellfish vaccine Development.
- Norwegian Research council 183205/S40 Havbruksprogrammet (2008-2011)

Training in connection with establishment in Vietnam.
- NORAD (2009-2011)

A combinatorial mutagenesis approach to improve microbial expression systems.
- Norwegian Research council 182627 (2008-2010).

Intracellular lifestyle of Francisella piscicida in Atlantic cod.
-Norwegian Research council (2010-2013)

External funded R&D projects, closed:

Påvirker avlsarbeidet for økt sjukdomsresistens forekomsten av vaksineskader, immunrespons og effekten av vaksinering?
- Nofima (2007-2010)

Immunity of Aquatic Animals - IMAQUANIM.
- 22 partners in Europe, including NVH, NFH and PHARMAQ (2005-2010)

Utvikling av en real time PCR metode for kvantifisering av ILA virus.
- MABIT (2010)

Bilateral cooperation on fish vaccine development for Chinese aquaculture.
- BILAT 190339 (2009)

Heart and Skeletal Muscle Inflammation (HSMI) - molecular characterisation of the virus and vaccine development.
- Fuge 176975 (2006-2009).

Characterisation of Piscirikettsia salmonis, infection and technology development for optimal vaccines against intracellular bacteria.
- Fuge 180208 (2007-2009).

Vaccines for the catfish (Pangasius sp.) industry in Vietnam.
- IFU project, development of vaccines to the industry in Vietnam (2006-2009).

Characterization of Francisella piscicida infection in Atlantic cod cells.
- MABIT. Two partners, including PHARMAQ (2009)